Product
2,000 mg controlled-release Ca-AKG a day
Three tablets a day, from Ponce De Leon Health (US). Prof Brian Kennedy (NUS) is a scientific advisor and board member. The women's formula adds vitamin D3 38 mcg (about 1,520 IU).
Rejuvant Professional
Doctor brief · Preliminary · Private and confidential
We are assessing whether to import Rejuvant Professional, a calcium alpha-ketoglutarate (Ca-AKG) supplement, for doctors to recommend at SLAC. Import is straightforward. The evidence is early and the claims we can make are narrow, so we need your view before ordering any stock.
Product
2,000 mg controlled-release Ca-AKG a day
Three tablets a day, from Ponce De Leon Health (US). Prof Brian Kennedy (NUS) is a scientific advisor and board member. The women's formula adds vitamin D3 38 mcg (about 1,520 IU).
Evidence
Two human studies, no placebo, half the dose
Open-label, n = 42: biological age −8 years at about 7 months. Cross-sectional, n = 4,260: −1.8 years, against a clock error of 5.4 years. Both used the 1,000 mg consumer product, with manufacturer-linked authors. No human data at 2,000 mg.
Controlled trial
ABLE at NUS will decide the case
Randomised, double-blind, placebo-controlled, 120 planned, 1 g Ca-AKG (NCT05706389). Main data collection ended Aug 2025. Muscle, bone, lifespan and skin findings are otherwise preclinical; no human study of oral AKG on skin.
Regulatory
Import in about 3–6 weeks
A qualifying health supplement needs no HSA pre-market approval. We would still own quality, Singapore labels and claims, and confirm the formula against HSA limits.
What doctors can say
Advice in consult, never in ads
One-to-one advice in consult is allowed. Doctor endorsements on labels, ads or promotions are not. No anti-ageing, biological age, skin-ageing or disease claims anywhere. SMC guidance on doctors selling health products also applies.
How it would be offered
Consult first, with an optional programme
Base case: you recommend it to existing SLAC patients. Option: PLMC's Longevity Blueprint (AgeQ blood test, grip, InBody; SGD 169) with retests at 6 and 12 months. AgeQ is blood-based; no study shows Ca-AKG moves it. OTC Ca-AKG sells at SGD 38–47 a pack; our price is not yet set.
Would you recommend Rejuvant Professional to suitable patients?
Yes, now · Only after ABLE reports · No
Which patients would you consider it for, and roughly how many a month?
Do you have safety or suitability concerns, such as the 2,000 mg dose, calcium or vitamin D load, or interactions?
Would you refer patients to PLMC's Longevity Blueprint to baseline and retest them?
Yes · Maybe · No
Is there anything you know about when ABLE will report, or evidence we have missed?
Sources: Demidenko et al., Aging, 2021; Pabis et al., Aging Cell, 2026; ClinicalTrials.gov NCT05706389; Rejuvant Professional data sheet RPTS0726; HSA health supplement guidance; prologueclinic.com; retail prices observed Oct 2026. Summarised from the Rejuvant Professional assessment of 12 Oct 2026.